Latest from AHIP

What’s Next in Health Care? Panelists Highlight Data, Partnerships Post-COVID-19

June 24, 2022

Panelists of an AHIP 2022 session discussed how future policy, infrastructure, and investment strategies in public health will reinforce the efforts already made during the pandemic, with partnerships and engagement key to optimize innovation.

Alignment Between Manufacturers, Payers Key to Improving Specialty Drug Affordability and Access

June 22, 2022

Panelists taking part in an AHIP 2022 session discuss collaborative strategies among payers, manufacturers, and policy makers to address challenges regarding affordability and access of novel disease modifying drugs entering the marketplace.

What We're Reading: US Birth Rates Rise; Plant Closure Foretells Drug Shortages; No Surprises Act Showing Effect

May 24, 2022

United States birth rate rises from last year but is still lower than pre-pandemic; a drug plant closure in California could affect availability of 5 essential medications; the No Surprises Act prevented 2 million potential surprise bills in first 2 months of 2022, report says.

To Advance Health Equity, Use the Data—Don’t Just Collect Them, Officials Say

June 23, 2021

At a session of AHIP 2021 Institute and Expo Online, the head of North Carolina's health and human services department and a health equity policy advisor in the Biden administration discussed how collecting and using data to achieve health equity is ultimately a policy decision.

Are Payment Reform Efforts Enough to Fix Future Medicare Financing Woes?

March 11, 2021

During a session presented at the America’s Health Insurance Plans (AHIP) National Health Policy Conference, Michael Chernew, PhD, the director of Healthcare Markets and Regulation Lab at Harvard Medical School, and Mark McClellan, MD, PhD, founding director at Duke Margolis Center for Health Policy, discussed the potential for Medicare innovation and reforms in 2021 and beyond.